Related references
Note: Only part of the references are listed.Host effects contributing to cancer therapy resistance
Ofrat Beyar Katz et al.
DRUG RESISTANCE UPDATES (2015)
Macrophages in multiple myeloma
Domenico Ribatti et al.
IMMUNOLOGY LETTERS (2014)
Differential Therapeutic Effects of Anti-VEGF-A Antibody in Different Tumor Models: Implications for Choosing Appropriate Tumor Models for Drug Testing
Dror Alishekevitz et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Anti-Bv8 Antibody and Metronomic Gemcitabine Improve Pancreatic Adenocarcinoma Treatment Outcome Following Weekly Gemcitabine Therapy
Erez Hasnis et al.
NEOPLASIA (2014)
Macrophage Regulation of Tumor Responses to Anticancer Therapies
Michele De Palma et al.
CANCER CELL (2013)
The host immunological response to cancer therapy: An emerging concept in tumor biology
Tali Voloshin et al.
EXPERIMENTAL CELL RESEARCH (2013)
Proteasome inhibitors in multiple myeloma: 10 years later
Philippe Moreau et al.
BLOOD (2012)
Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells
Jaehyup Kim et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Role of Interleukin 16 in Multiple Myeloma
Djordje Atanackovic et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
S. K. Kumar et al.
LEUKEMIA (2012)
miR-511-3p Modulates Genetic Programs of Tumor-Associated Macrophages
Mario Leonardo Squadrito et al.
CELL REPORTS (2012)
G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: prevention by a CXCR4 antagonist
Tali Voloshin et al.
BLOOD (2011)
Host Response to Short-term, Single-Agent Chemotherapy Induces Matrix Metalloproteinase-9 Expression and Accelerates Metastasis in Mice
Svetlana Gingis-Velitski et al.
CANCER RESEARCH (2011)
Chemotherapy Enhances Metastasis Formation via VEGFR-1-Expressing Endothelial Cells
Laura G. M. Daenen et al.
CANCER RESEARCH (2011)
Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer
Tanaya Shree et al.
GENES & DEVELOPMENT (2011)
TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice
Abigail F. Welford et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy
David G. DeNardo et al.
CANCER DISCOVERY (2011)
Angiogenesis and Multiple Myeloma
Nicola Giuliani et al.
CANCER MICROENVIRONMENT (2011)
Different Tumor Microenvironments Contain Functionally Distinct Subsets of Macrophages Derived from Ly6C(high) Monocytes
Kiavash Movahedi et al.
CANCER RESEARCH (2010)
Interleukin-6 leads to interleukin-10 production in several human multiple myeloma cell lines. Does interleukin-10 enhance the proliferation of these cells?
Eva Kovacs
LEUKEMIA RESEARCH (2010)
A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood resident monocytes, and embryonic macrophages suggests common functions and developmental relationships
Ferdinando Pucci et al.
BLOOD (2009)
Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis
Yuhuan Zheng et al.
BLOOD (2009)
Matrigel cytometry: A novel method for quantifying angiogenesis in vivo
A. Adini et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2009)
Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)
E. Kastritis et al.
LEUKEMIA (2009)
Many facets of bortezomib resistance/susceptibility
Shaji Kumar et al.
BLOOD (2008)
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: Implications for antiangiogenic drugs as chemosensitizing agents
Yuval Shaked et al.
CANCER CELL (2008)
Cancer-related inflammation
Alberto Mantovani et al.
NATURE (2008)
Molecular origins of cancer: Tumor angiogenesis
Robert S. Kerbel
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The tumor microenvironment and its role in promoting tumor growth
T. L. Whiteside
ONCOGENE (2008)
Successful Inhibition of Tumor Development by Specific Class-3 Semaphorins Is Associated with Expression of Appropriate Semaphorin Receptors by Tumor Cells
Boaz Kigel et al.
PLOS ONE (2008)
Improved survival in multiple myeloma and the impact of novel therapies
Shaji K. Kumar et al.
BLOOD (2008)
Semaphorin-3A and semaphorin-3F work together to repel endothelial cells and to inhibit their survival by induction of apoptosis
Noga Guttmann-Raviv et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Antiangiogenic strategies on defense: On the possibility of blocking rebounds by the tumor vasculature after chemotheraphy
Yuval Shaked et al.
CANCER RESEARCH (2007)
Patterns of survival in multiple myeloma:: A population-based study of patients diagnosed in Sweden from 1973 to 2003
Sigurdur Yngvi Kristinsson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors
Yuval Shaked et al.
SCIENCE (2006)
Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells
AM Roccaro et al.
CANCER RESEARCH (2006)
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma
S Lonial et al.
BLOOD (2005)
A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells
D Chauhan et al.
CANCER RESEARCH (2005)
Expression of EGF-family receptors and amphiregulin in multiple myeloma.: Amphiregulin is a growth factor for myeloma cells
K Mahtouk et al.
ONCOGENE (2005)
Stromal fibroblasts in cancer initiation and progression
NA Bhowmick et al.
NATURE (2004)
Molecular sequelae of proteasome inhibition in human multiple myeloma cells
N Mitsiades et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Neuropilin-2 and neuropilin-1 are receptors for the 165-amino acid form of vascular endothelial growth factor (VEGF) and of placenta growth factor-2, but only neuropilin-2 functions as a receptor for the 145-amino acid form of VEGF
Z Gluzman-Poltorak et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
